Who is sponsoring NCT06287411?

NCT06287411 is sponsored by Xiao Chen.

What drugs are being tested in NCT06287411?

Interventions in NCT06287411: FAPI PET/MR combined with gadoxetate disodium.

What condition does NCT06287411 study?

NCT06287411 studies Hepatic Malignancies.

Is NCT06287411 still recruiting?

NCT06287411 is currently status unknown. Last updated 5 March 2024.

Last reviewed 2024-03-05 · How we verify

NCT06287411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

Status unknown Last updated 5 March 2024

What this trial tests

trial testing FAPI PET/MR combined with gadoxetate disodium in Hepatic Malignancies in 36 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Xiao Chen
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	36
Start date	1 December 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

FAPI PET/MR combined with gadoxetate disodium

Conditions studied

Hepatic Malignancies — all drugs for Hepatic Malignancies →

Sponsor

Xiao Chen

Who can join

18 and older, any sex, with Hepatic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xiao Chen trials

Trials by the same sponsor.

NCT06234319 — CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma · unknown
NCT06318234 — PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer · unknown
NCT06183554 — CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism · unknown
NCT05824962 — A Non-invasive Diagnostic Model for Intestinal Fibrosis in Crohn's Disease Based on 18F-FAPI PET Imaging · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06287411 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiao Chen
Last refreshed: 5 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06287411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing